His primary areas of investigation include Endocrinology, Internal medicine, Insulin, Diabetes mellitus and Type 2 diabetes. As part of his studies on Endocrinology, Peter R. Flatt frequently links adjacent subjects like Dipeptidyl peptidase. Glucose homeostasis, Incretin, Receptor, Islet and Glucagon are among the areas of Internal medicine where the researcher is concentrating his efforts.
His work deals with themes such as Biological activity and Carbohydrate metabolism, Biochemistry, Peptide, which intersect with Insulin. In his research on the topic of Diabetes mellitus, Botany, Sativum and Coriandrum is strongly related with Traditional medicine. His Type 2 diabetes research includes elements of Metformin and Enzyme.
Peter R. Flatt mainly investigates Internal medicine, Endocrinology, Insulin, Diabetes mellitus and Biochemistry. His Internal medicine research integrates issues from Glucagon-like peptide-1, Peptide and Streptozotocin. Endocrinology is a component of his Glucose homeostasis, Type 2 diabetes, Glucagon, Beta cell and Insulin resistance studies.
His Insulin study integrates concerns from other disciplines, such as Biological activity and Pharmacology. His biological study spans a wide range of topics, including Hormone and Obesity. A large part of his Biochemistry studies is devoted to Amino acid.
Peter R. Flatt mainly focuses on Internal medicine, Endocrinology, Insulin, Diabetes mellitus and Islet. His Internal medicine research incorporates themes from Liraglutide and Peptide. His study in Endocrinology focuses on Glucagon, Beta cell, Type 2 diabetes, Streptozotocin and Insulin resistance.
His study in Insulin is interdisciplinary in nature, drawing from both Hormone, Glucagon-like peptide-1 and Pharmacology. His Diabetes mellitus study combines topics in areas such as Obesity and Neuroprotection. The Islet study combines topics in areas such as Neuropeptide and Peptide YY.
The scientist’s investigation covers issues in Internal medicine, Endocrinology, Insulin, Diabetes mellitus and Beta cell. Internal medicine is closely attributed to Streptozotocin in his work. His Endocrinology study frequently links to adjacent areas such as Xenin.
His research integrates issues of In vitro, Glucagon-like peptide-1, Type 2 diabetes, Fatty acid and Neurogenesis in his study of Insulin. The concepts of his Diabetes mellitus study are interwoven with issues in Hormone, Receptor and Neuroprotection, Pharmacology. His Beta cell research is multidisciplinary, incorporating elements of Arginine vasopressin receptor 2, Posterior pituitary, Genetic enhancement, Cell therapy and Vasopressin receptor.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Traditional plant treatments for diabetes. Studies in normal and streptozotocin diabetic mice
S. K. Swanston-Flatt;C. Day;C. J. Bailey;P. R. Flatt.
Abnormal plasma glucose and insulin responses in heterozygous lean (ob/+) mice.
P. R. Flatt;C. J. Bailey.
Insulin-releasing and insulin-like activity of the traditional anti-diabetic plant Coriandrum sativum (coriander).
Alison M. Gray;Peter R. Flatt.
British Journal of Nutrition (1999)
Characterization of a Novel Glucose-Responsive Insulin-Secreting Cell Line, BRIN-BD11, Produced by Electrofusion
Neville H McClenaghan;Christopher R Barnett;Eric Ah-Sing;Yasser H A Abdel-Wahab.
The effects of traditional antidiabetic plants on in vitro glucose diffusion
Alison Gallagher;Peter Flatt;G Duffy;Yasser Abdel-Wahab.
Nutrition Research (2003)
Soluble dietary fibre fraction of Trigonella foenum-graecum (fenugreek) seed improves glucose homeostasis in animal models of type 1 and type 2 diabetes by delaying carbohydrate digestion and absorption, and enhancing insulin action
J. M. A. Hannan;L. Ali;B. Rokeya;J. Khaleque.
British Journal of Nutrition (2007)
Glycaemic effects of traditional European plant treatments for diabetes. Studies in normal and streptozotocin diabetic mice.
S K Swanston-Flatt;C Day;P R Flatt;B J Gould.
Diabetes research (Scotland) (1989)
Dipeptidyl peptidase IV (DPP IV) inhibitors: A newly emerging drug class for the treatment of type 2 diabetes
Brian D Green;Peter R Flatt;Clifford J Bailey.
Diabetes and Vascular Disease Research (2006)
Inhibition of dipeptidyl peptidase IV activity by oral metformin in Type 2 diabetes
John Lindsay;Nicola Duffy;Aine Mckillop;Joy Ardill.
Diabetic Medicine (2005)
The Traditional Plant Treatment, Sambucus nigra (elder), Exhibits Insulin-Like and Insulin-Releasing Actions In Vitro
Alison M. Gray;Yasser H. A. Abdel-Wahab;Peter R. Flatt.
Journal of Nutrition (2000)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: